AstraZeneca Pharmaceuticals LP
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of[...]
05/09/2024 | Press release | Distributed by Public on 05/09/2024 16:29
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact